Dr Reddys to provide 2 percent royalty to DRDO on anti-COVID drug 2-DG sale in India
The drug comes in powder form in sachet and is taken orally by dissolving it in water.
New Delhi: The Defence Research and Development Organisation (DRDO) will get two per cent royalty from Dr Reddy's Laboratory (DRL) on the sale of anti-COVID drug 2-DG, Minister of State for Defence Ajay Bhatt said on Wednesday.
In a written reply to a question in the Lok Sabha, Bhatt said the DRDO developed the technology (for 2-DG) along with DRL, Hyderabad. The pricing is solely decided by DRL. The actual price fixed by Dr Reddy lab is Rs 990 per sachet, he said.
The DRDO works under the Defence Ministry. DRL is a private listed company.
"DRDO will get 2 per cent royalty on the sale of 2-DG in the Indian market as per Transfer of Technology agreement," Bhatt said.
The Drugs Controller General of India (DCGI) approved the 2-deoxy-D-glucose (2-DG) drug for emergency use as an adjunct therapy in moderate to severe coronavirus patients in early May.
The first batch of this oral drug, developed by the DRDO was released on May 17 by Defence Minister Rajnath Singh and then Health Minister Harsh Vardhan.
The Defence Ministry on May 8 had said that the clinical trials of 2-DG showed that it helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence.
The drug comes in powder form in sachet and is taken orally by dissolving it in water.
Read also: Dr Reddys launches oral anti-COVID drug 2-DG commercially
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.